Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMycelx Di Regulatory News (MYX)

Share Price Information for Mycelx Di (MYX)

Share Price is delayed by 15 minutes
Get Live Data
66.00    1.50 (2.33%)
Bid:
64.00
Ask:
68.00
Spread: 4.00 (6.25%)
Market Cap: £16.08m
MYX Live PriceLast checked at - London Stock Exchange

Intraday Mycelx Di Share Chart

Director/PDMR Shareholding

30 May 2017 13:19

RNS Number : 5853G
MyCelx Technologies Corporation
30 May 2017
 

MYCELX Technologies Corporation

("MYCELX" or the "Company") (AIM: MYX)

30 May 2017

 

 

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). This inside information is now considered to be in the public domain.

 

Grant of Share Option to Chief Financial Officer

 

On 26 May 2017 Ms. Slayton was awarded the following options over the Company's common shares of US$0.025 each ("Common Shares") under the MYCELX Omnibus Performance Incentive Plan ("Plan"):

 

Name

Number of share options granted

Exercise price

Total number of share options held following this notification

Total number of share options as % of current issued share capital

Kimberly Slayton

30,000

US$0.75*

130,000

0.69%

 

Ms. Slayton holds no Common Shares in the issued capital of the Company.

 

Grant of Share Option to Chief Business Development Officer

 

The Company further announces that Mark Mixon, Chief Business Development Officer, was granted an option on 26 May 2017 under the Plan over 35,000 Common Shares. The grant to Mr. Mixon was as follows:

 

Name

Number of share options granted

Exercise price

Total number of share options held following this notification

Total number of share options as % of current issued share capital

Mark Mixon

35,000

US$0.75*

300,204

1.60%

 

In addition, following this transaction, Mr. Mixon continues to be interested in 10,000 Common Shares, representing 0.05 per cent of the present issued capital of the Company, which he holds as a custodian.

 

Grant of Share Option to Chief Executive Officer

 

The Company further announces that Connie Mixon, Chief Executive Officer, was granted an option on 26 May 2017 under the Plan over 40,000 Common Shares. The grant to Ms. Mixon was as follows:

 

Name

Number of share options granted

Exercise price

Total number of share options held following this notification

Total number of share options as % of current issued share capital

Connie Mixon

40,000

US$0.75*

203,017

1.08%

 

 

Following this award, Connie Mixon, Chief Executive Officer and spouse of Mr. Mixon is interested in an aggregate (including the interests of Mr. Mixon) of 991,211 Common Shares, representing 5.28 per cent of the present issued capital of the Company, and in options over an aggregate (including the interests of Mr. Mixon) of 503,221 Common Shares, representing 2.68 per cent of the present issued capital of the Company.

 

The aggregate number of Common Shares held by Ms. Mixon also includes (a) 150,000 shares held by limited liability companies controlled by Ms. Mixon; and (b) 202,646 shares held by or on behalf of Ms. Mixon's children.

 

The above grants formed part of wider grants of 205,000 options to employees across the Company, on the same date, representing 1.09% of the current issued share capital.

 

The share options granted on 26 May 2017 will vest as to 50% on 31 December 2017 and 50% on 31 December 2018, and must be exercised prior to the tenth anniversary of the date of grant, subject to the restrictions on dealing under the Company's share dealing code.

 

Following the above grants, a total of 1,192,042 share options have been granted to directors and employees and are currently outstanding, representing 6.35% of the issued share capital of 18,770,117 Common Shares. *Based on the closing mid-market price of the Company's Common Shares at 26 May 2017, and the closing US/£ exchange rate at that date.

 

For further information please contact:

 

MYCELX Technologies Corporation

Connie Mixon, CEO

Kim Slayton, CFO

 

Tel: +1 888 306 6843

Cantor Fitzgerald Europe - NOMAD and Broker

Andrew Craig

Richard Salmond

 

Tel: +44 20 7894 7000

Celicourt Communications

Mark Antelme

Joanna Boon

 

Tel: +44 20 7520 9266

 

The relevant notifications set out below are provided in accordance with the requirements of Article 19 of the EU Market Abuse Regulation (No. 596/2014).

Notification of transactions of persons discharging managerial responsibility or connected persons

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Connie Mixon

 

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Director

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Mycelx Technologies Corporation

b)

 

LEI

 

 

213800UJZINIK2VD1G48

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

 

 

Common shares of US$0.025

 

USU624551078

 

 

b)

 

Nature of the transaction

 

 

Grant of share option to Connie Mixon under the Mycelx Omnibus Performance Incentive Plan

 

 

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

 

US$0.75

 

40,000

 

 

d)

 

Aggregated information

 

 

- Aggregated volume

 

 

- Price

 

 

 

 

 

n/a

 

 

n/a

 

 

e)

 

Date of the transaction

 

 

2017/05/26

f)

 

Place of the transaction

 

 

Grant of the options occurred outside a trading venue.

 

 

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Connie Mixon

 

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Director

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Mycelx Technologies Corporation

b)

 

LEI

 

 

213800UJZINIK2VD1G48

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

 

 

Common shares of US$0.025

 

USU624551078

 

 

b)

 

Nature of the transaction

 

 

Grant of share option to spouse, Mark Mixon, under the Mycelx Omnibus Performance Incentive Plan

 

 

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

 

US$0.75

 

35,000

 

 

d)

 

Aggregated information

 

 

- Aggregated volume

 

 

- Price

 

 

 

 

 

n/a

 

 

n/a

 

 

e)

 

Date of the transaction

 

 

2017/05/26

f)

 

Place of the transaction

 

 

Grant of the options occurred outside a trading venue.

 

 

 

 

Notes to Editors

MYCELX is a revolutionary oil-free water technology company solving the world's toughest oil removal problems in the oil and gas industry. The systems are based upon scientific breakthrough for a completely different approach to permanent oil removal. The Company created the patented MYCELX polymer using innovative molecular cohesion for removing oil from water far beyond what conventional systems have ever achieved. MYCELX systems remove oil to critically low levels in a much smaller physical footprint than conventional systems and in a virtually fail-safe process.

www.mycelx.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHLLFLFETIIVID
Date   Source Headline
3rd Jun 20267:00 amRNSAppointment of Non-Executive Director
12th May 20267:00 amRNSNew Gulf of Mexico Lease Award with Super Major
7th May 20267:00 amRNSFinal Results for the Year Ending 31 December 2025
16th Feb 202610:46 amRNSDirector Dealing
20th Jan 20267:00 amRNSTrading Update
22nd Dec 202511:27 amRNSHolding(s) in Company
7th Nov 20252:51 pmRNSHolding(s) in Company
3rd Nov 20257:00 amRNSTrading Update & $3.9m Project Award
1st Oct 20257:00 amRNSHolding(s) in Company
23rd Sep 20255:00 pmRNSResult of Annual Meeting
23rd Sep 20257:00 amRNSAppointment of New Chairman and Succession
17th Sep 20257:00 amRNSHalf Year Results Statement
11th Sep 20257:00 amRNSClosure of Restricted Stock Line
22nd Aug 20257:00 amRNSMailing of Notice of 2025 Annual Meeting
20th Aug 20257:00 amRNSOpening of $500,000 Line of Credit
17th Jul 20257:00 amRNSTrading Update
10th Jun 20257:00 amRNSMailing of 2024 Annual Report
21st May 20253:25 pmRNSDirector Dealing
19th May 202511:33 amRNSHolding(s) in Company
15th May 202511:21 amRNSHolding(s) in Company
12th May 20257:00 amRNSFinal Results for the Year Ending 31 December 2024
6th May 20257:00 amRNSPFAS Contract Award
1st May 20257:00 amRNS-REPA Announces Actions to Combat PFAS Contamination
10th Apr 20257:00 amRNSGrant of Share Options
7th Apr 20257:00 amRNSOperational and Trading Update
30th Jan 20257:00 amRNSChange of Adviser
6th Jan 20257:00 amRNSYear-end Update
29th Oct 20247:00 amRNSProject Award
24th Sep 20247:00 amRNSHalf Year Results Statement
23rd Sep 20247:00 amRNSTrading Update
6th Sep 202411:54 amRNSHolding(s) in Company
5th Sep 20245:17 pmRNSHolding(s) in Company
30th Aug 20247:00 amRNSBroker Option
23rd Aug 202411:05 amRNSDirector Dealings & Total Voting Rights
23rd Aug 20247:00 amRNSProposed Placing and Subscription
19th Jul 202410:36 amRNSPFAS Update
9th Jul 20242:23 pmRNSResult of AGM
9th Jul 20241:39 pmRNSHolding(s) in Company
4th Jun 20247:00 amRNS2023 Annual Report & Notice of 2024 Annual Meeting
21st May 20247:00 amRNSDirector Dealing
16th May 20247:00 amRNSFinal Results for the Year Ending 31 December 2023
24th Apr 20247:00 amRNSBusiness Update
11th Apr 20247:00 amRNSEPA Publishes National Drinking Water Standards
26th Mar 20243:30 pmRNSDirector Dealing
26th Mar 20247:00 amRNSDirector Dealing
22nd Mar 20247:00 amRNSDirector Dealing
21st Mar 20247:00 amRNSDirector Dealing
18th Mar 20247:00 amRNSGrant of Share Options to Chief Financial Officer
4th Mar 20247:00 amRNSSaudi Arabia Business Operation Sale Completion
22nd Feb 20247:02 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.